Immunotherapy for autoimmune and inflammatory renal diseases.
New treatments for autoimmune renal disease are required, and a developing knowledge of its underlying immunopathogenesis has identified sites where immunotherapy is likely to be effective. Experience with intravenous immunoglobulin and lymphocyte depletion by monoclonal antibodies in systemic vasculitis and systemic lupus erythematosus is awaiting confirmation by randomized trials. Treatments at or near clinical testing include monoclonal antibody blockade of leucocyte-endothelial interactions and CD40 mediated B-cell activation, and immunoablation with autologous stem-cell transplantation for more severe multisystem autoimmune disease.
Jayne
D R
DR
Division of Renal Medicine, St George's Hospital Medical School, London, UK. djayne@sghms.ac.uk
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001323:Autoantibodies / Q000096:biosynthesis / Q000302:isolation & purification; D001327:Autoimmune Diseases / Q000628:therapy; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007108:Immune Tolerance; D007130:Immunoglobulin Idiotypes / Q000378:metabolism; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007167:Immunotherapy; D007674:Kidney Diseases / Q000628:therapy*; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D009393:Nephritis / Q000628:therapy; D014657:Vasculitis / Q000628:therapy
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D016207:Cytokines; D007130:Immunoglobulin Idiotypes; D016756:Immunoglobulins, Intravenous